OCULAR THERAPEUTIX, INC Revenues
OCULAR THERAPEUTIX, INC (OCUL) reported Revenues of $504.00 thousand for the 3-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2019-03-07
- OCULAR THERAPEUTIX, INC revenues for the quarter ending 2018-12-31 was $504.00K, a 3.49% increase year-over-year.
- OCULAR THERAPEUTIX, INC revenues for the quarter ending 2018-09-30 was $498.00K, a 4.78% decline year-over-year.
- OCULAR THERAPEUTIX, INC revenues for the quarter ending 2018-06-30 was $648.00K, a 47.95% increase year-over-year.
- OCULAR THERAPEUTIX, INC revenues for the quarter ending 2018-03-31 was $340.00K, a 28.42% decline year-over-year.
- OCULAR THERAPEUTIX, INC revenues for fiscal 2018 was $1.99M, a 3.48% increase from fiscal 2017.
- OCULAR THERAPEUTIX, INC revenues for fiscal 2017 was $1.92M, a 1.91% increase from fiscal 2016.
- OCULAR THERAPEUTIX, INC revenues for fiscal 2016 was $1.89M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-12-31 | $504.00K 10-K · filed 2019-03-07 | $1.00M derived: sum of 2 quarters · filed 2019-03-07 | $1.65M derived: sum of 3 quarters · filed 2019-03-07 | $1.99M 10-K · filed 2019-03-07 |
| 2018-09-30 | $498.00K 10-K · filed 2019-03-07 | $1.15M derived: sum of 2 quarters · filed 2019-03-07 | $1.49M 10-Q · filed 2018-11-07 | $1.97M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-06-30 | $648.00K 10-K · filed 2019-03-07 | $988.00K 10-Q · filed 2018-08-07 | $1.48M derived: sum of 3 quarters · filed 2019-03-07 | $2.00M derived: sum of 4 quarters · filed 2019-03-07 |
| 2018-03-31 | $340.00K 10-K · filed 2019-03-07 | $827.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.35M derived: sum of 3 quarters · filed 2019-03-07 | $1.79M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-12-31 | $487.00K 10-K · filed 2019-03-07 | $1.01M derived: sum of 2 quarters · filed 2019-03-07 | $1.45M derived: sum of 3 quarters · filed 2019-03-07 | $1.92M 10-K · filed 2019-03-07 |
| 2017-09-30 | $523.00K 10-K · filed 2019-03-07 | $961.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.44M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $438.00K 10-K · filed 2019-03-07 | $913.00K 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $475.00K 10-K · filed 2019-03-07 | |||
| 2016-12-31 | $1.89M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |